Portfolio overview
OBIGEN Pharma. The first biotechnology startup company in Taiwan that engages in the research, development, production and manufacturing of botulinum toxin.
AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
Anbogen Therapeutics is a clinical-stage biotech company dedicated to designing and developing precision oncology therapies to improve patients' lives. Founded by a group of exceptional scientists committed to bridging the gap between research and clinical development. Our mission is to create breakthrough science that transforms the lives of cancer patients.
YJ Biotech possesses three key technologies and more than 12 exclusive patents. It is also the first in Taiwan to follow the GMP standard to establish a cell preparation site (CPU) using "Pharmaceutical Isolation Equipment (YJ-Isolator)", which has been recognized and verified by the GTP under the Regulations of Special Medical Techniques. Our PIC/S GMP-in-Design Cell Manufacturing Platform continually breaks through the technological boundaries of cell manufacturing. It provides an all-in-one service to meet the needs of various cells and their derivatives, such as exosomes, for treating multiple diseases and cancers.
Tripartite Therapeutics focuses on the development of proprietary platform technologies for targeted delivery of therapeutics with the potential to generate a continuous pipeline of best-in-class targeted delivery treatments to satisfy unmet medical needs in oncology, metabolic diseases and beyond.
Uwell Biopharma focuses on Chimeric Antigen Receptor T-cell (CAR-T) technology as its core platform, establishing an integrated technology system covering vector design, cell process development, GMP manufacturing, and clinical trials.
ARCE is developing first-in-class and best-in-class CAR-T/CAR-NK cell therapy products for the treatment of various forms of cancers, including hematological cancers and solid tumors. ARCE provides state-of-the-art products of new generation CAR-T/CAR-NK cell therapy, to make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
TLC BioSciences is a clinical‑stage biotechnology company advancing lipid‑engineered medicines across metabolic, orthopedic, and immune‑cell therapy. Our proprietary LipAD® family of platforms—including BioSeizer® sustained‑release technology, NanoX® active drug‑loading systems, and next‑generation targeted lipid nanoparticles (tLNP)—enables long‑acting, targeted, and programmable delivery for a wide range of therapeutic modalities.
Our vision is to push the boundaries of artificial intelligence to solve complex challenges and shape a better future. We’re passionate about creating intelligent solutions that drive meaningful change across industries and communities. Through innovation, collaboration, and a commitment to excellence, we aim to set new standards in AI development.
Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients.
Founded in 2020, AcadeMab Biomedical Inc.s a start-up company dedicated to the development of new antibody drugs in the medical field that require urgent breakthroughs.
We are dedicated to establishing a drug discovery and early-stage development company that is based on innovation, scientific rigor and integrity. Our goal is to create novel products to meet critical patient needs, including: Novel imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases; and Novel therapies to improve the treatment of human neurological conditions.
Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients.
UBI Pharma was established on July 31, 2014 as a spin-off company from United Biomedical, Inc., Asia. UBI Pharma specializes in developing and manufacturing fusion protein drugs and formulations of small molecule pharmaceuticals.
Foresee Pharmaceuticals Co., Ltd. (FP) is a clinical-stage pharmaceutical company. Our mission is to serve patients. We strive to improve patients' quality of life and provide cure through innovative research. We are committed to apply the highest ethical standards to our products, services and communications. Foresee's core competency includes rapid development and commercialization of new drugs using its proprietary drug delivery technology as well as develop first-in-class NCE in disease areas of high unmet medical needs.
BioFirst Corporation focuses on the research, development, manufacture, and marketing of pharmaceutical products in Taiwan. The company develops products focusing on the clinical application of biomedical materials. It is developing FibroTest, a non-invasive liver disease detection system; Clover A1c, a HbA1c timely detection system; and GlucoPet A1C, a pet blood glucose monitoring system. The company was founded in 2006 and is headquartered in Taipei, Taiwan.
Based on the development work, NTI is developing a patent portfolio in order to protect the commercialization of this novel therapeutic technique.
SynCore Biotechnology Co., Ltd (“SynCore”) is a biopharmaceutial company focusing on creating values of new drug by R&D and integration of technology resources.
Savior Lifetec Corporation (SLC) is a specialty injectable company based in Chunan, Taiwan. Their facilities comply with the highest quality standards, having passed inspections by authorities from the US, EU, and Japan. SLC also has dedicated state-of-the-art GLP compliant R&D centers for API research and pharmaceutical research.
